Abstract
The anti-inflammatory activity of curcumin, Curcuma longa, is known, however, its low bioavailability is a limiting factor. The nanoencapsulated curcumin was developed and its spherical particle size ∼20 nm was confirmed using TEM. An in vitro study was performed to determine the cytotoxicity of standard and nanoencapsulated curcumin, and their effect on lipopolysaccharide-induced nitric oxide, and IL-6 production in RAW 264.7 cells. The plasma bioavailability of nanoencapsulated curcumin was 12 times higher compared to native curcumin in Swiss albino mice. The anti-inflammatory activity of native curcumin and nanoencapsulated curcumin was compared in the carrageenan-induced paw edema model. A paw thickness reduction of 33.7 % and 46 % was observed with the treatment of native curcumin and nanoencapsulated curcumin, respectively and the histology studies validated the results. Further, the in vitro COX-1 inhibition of cookies incorporated with nanoencapsulated curcumin was 20 and 24 % higher than native curcumin and control cookies, respectively indicating their nutraceutical application.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call